

This presentation is not intended to and does not constitute or form part of any offer, or invitation, or solicitation of any offer to issue, underwrite, subscribe for, or otherwise acquire or dispose of any shares or other securities of Ovoca Bio plc (the "Company") in any jurisdiction or an inducement to enter into investment activity.

No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. The presentation contains forward-looking statements, including statements about the Company's intentions, beliefs and expectations.

These statements are based on the Company's current plans, estimates and projections, as well as the Company's expectations of external conditions and events. Forward-looking statements involve inherent risks and uncertainties, are based on certain assumptions and speak only as of the date they are made.

The Company undertakes no duty to and will not necessarily update any such statements in light of new information or future events, except to the extent required by any applicable law or regulation.

Recipients of this presentation are therefore cautioned that a number of important factors could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser.



Ovoca Bio plc



European-based biopharmaceutical company with a focus on **WOMEN'S health** Developing BP-101 a novel synthetic peptide for treatment of women with hypoactive sexual desire disorder (HSDD)

Affects more than ~4 million US women, two marketed treatments with significant side effect profiles

BP-101 is clinically validated, with Phase II and Phase III studies conducted in Russia, and Phase II underway in Australia/New Zealand

Submitted for marketing approval of BP-101 in Russia and seeking to develop in major **global** markets Founded in 1985 and incorporated in Republic of Ireland

AIM and ESM-quoted (AIM/ ESM:OVB/OVXA) >US\$15 million in cash and liquid assets to support drug development activities (June 2020)

Experienced


management team and top technical advisors in place to deliver on corporate goals.

About hypoactive sexual desire disorder (HSDD)

- Estimated one in ten premenopausal women have HSDD, making it one of the most common female sexual problems
- Defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM) as distressing and persistent deficiency of sexual fantasies and desire for sexual activity
- HSDD can have major effects on patients' ability to enjoy a fulfilling sex life and can be driven by a myriad of factors
- Diagnosis is via a variety of short screening tools, such as Decreased Sexual Desire Screener, to determine if a woman is affected by HSDD



Scale of the Problem that is HSDD



Estimated >4 million US women affected

Sources: 1 2015 US Census, 2. Obstet Gynecol 2008 112(5):970-8; Arch Intern Med 2008 168(13):1441-9; J Women's Health (Larchmt) 2012 21(5):505-15, 3. J Women's Health (Larchmt) 2012 21(5):505-15, 4. J Women's Health (Larchmt) 2009 18:461-468; J Women's Health (Larchmt) 2012 21(5):505-15; J Women's Health (Larchmt) 2014 23:817-823, 5. Obstet Gynecol 2008 112(5):970-8



Novel Treatments for HSDD in Premenopausal Women

Main competitors comparison


Drug	Administration	Frequency	Safety	Product	Dev. Stage
О \⊕С ∧во "вр-101"	Intranasal	Daily	No withdrawals due to AE (in 177 treated females)		Pre-MA in Russia Ph. 2 in West
Addyi [®] (flibanserin)	Oral	Daily (bedtime)	Black box warning, syncope and hypotension, use with alcohol restricted		Approved US only – August 2015
P A L A T I N TECHNOLOGIES, INC. Vyleesi® (Bremelanotide)	Subcutaneous injection	On demand 45 mins before sexual activity	AEs leading to CT withdrawal (rise of blood pressure, nausea)	and the second sec	Approved US only – July 2019

Ovoca's approach - BP-101


- Novel synthetic peptide conveniently administered through a nasal spray.
- Validated in Russian Phase II and Phase III studies
 - Demonstrated statistically significant and clinically meaningful improvement in a number of key efficacy outcomes in HSDD.
- Clinically significant increase in female sexual desire and reduces symptoms of distress associated with HSDD

Φ

STRONG EFFFICACY PROFILE – PHASE 3 FINDINGS



BP-101: A history of investment and progress



Safety profile

Favorable safety profile across all completed studies:

- No drug-related serious or severe adverse events
- 100% patient adherence to treatment (no patient withdrew from the study due to adverse events)

	Adverse Event	BP-101 (N=95)	Placebo (N=94)		
	All patients with adverse events	33 (34.7%) / 81	29 (30.9%) / 76		
Phase 3	Common adverse events (≥5% irrespective of causality, all Mild-to-Moderate):				
safety findings	Nasal irritation (several types)	11 (11.6%) / 23	1 (1.1%) / 6		
	Headache	6 (6.3%) / 12	9 (9.6%) / 17		
	Menstruation disorders (delays etc.)	5 (5.3%)/ 5	2 (2.1%)/ 3		

The table displays numbers and percentages (based on N) of subjects with adverse events (AEs) and numbers of AEs.


International Development Program

Building Ovoca's status as an international biotech company

- Validation of Russian clinical trial data in the West
 - Phase II dose ranging study enrolling in AUS/NZ Q1 2021
- BfArM and FDA advisory meetings held
- Commencement in 2021 of non-clinical studies in Europe enabling long term human dosing
- Exploration of a different dosing regimen and application in other sexual disorders
 - Suitability of on demand dosing for long term use
 - Potential use in Female Orgasmic Disorder

 $\bigcirc \lor \oplus \bigcirc$

• Advice from an international panel of experts in female sexual dysfunction




BP-101 - Phase II Dose Ranging Study

- Double-blind placebo-controlled study to enroll >450 patients across 13 sites in Australia and New Zealand commenced enrolment in Q1 2021
- Drug supplied by experienced, high quality contract manufacturers in Switzerland (Bachem) and the UK (Upperton)
- Aims to further validate the results of the Russian studies and provide evidence of efficacy in a Western culture
- Provides data fully compliant with the standards of the International Conference on Harmonisation supportive of a clinical programme in the US and EU.



Intellectual Property Protecting the company's most valuable asset



«Method for Producing a Recombinant Peptide and Resultant Peptide», priority year 2012.

- USA patent US9409947B2
- Japan patent 特第6552960
- Israel patent 234753
- EU patent 2876113
- India patent 349465
- **S Korea** patent 2876113

- Russia patent № 2507212, and also
 New patent № 2626002, priority year 2016, "New group of peptides for treatment of Female Sexual Dysfunction".
 - New patent № 2655763, priority year 2016,
 "Pharmaceutical composition and method of treatment of Female Sexual Dysfunctions"

PCT APPLICATIONS PROSECUTED IN:

US

EU

BRAZIL

CANADA

CHINA

INDIA

ISRAEL

JAPAN

SOUTH KOREA

Summary

- HSDD represents significant area of unmet medical need with high prevalence in valuable US and European markets
- Ovoca Bio's novel therapeutic approach offers potential advantages over existing approved treatments
 - Demonstrated statistically significant and clinically meaningful improvements in a number of key efficacy outcomes in HSDD
 - Shown as safe and well tolerated
 - Convenient dosing form
 - Strong clinical results in Russia being tested in Australia/New Zealand
- Strong financial position and **fully funded** to deliver near term goals
- Experienced management team with focus on delivering value



Thank you for your attention!

www.ovocabio.com

1110/00